Side-by-side · Research reference
PNC-27vsSermorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED18/41 cited
BPhase 3HUMAN-REVIEWED14/43 cited
PNC-27
p53-HDM-2 Peptide · Membrane-Targeting
In vitro / Pre-clinical only
Sermorelin
GHRH 1-29 fragment · Short-acting
SQ · Pre-sleep · 1×/day
01Mechanism of Action
Parameter
PNC-27
Sermorelin
Primary target
Membrane-bound HDM-2 protein on cancer cell surfaceSarafraz-Yazdi 2022Krzesaj 2024
Pituitary GHRH receptorWalker 1994
Pathway
PNC-27 binds to membrane HDM-2 1-109 domain → transmembrane pore formation → rapid necrosis (poptosis)Pincus 2024Krzesaj 2024
GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994
Downstream effect
Immediate cell lysis and extrusion of intracellular contents; secondary mitochondrial membrane disruptionPincus 2024Krzesaj 2024
Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013
Feedback intact?
N/A — cytotoxic mechanism, not signaling modulation
Yes — short pulse preserves feedback
Origin
Chimeric design: p53 transactivating domain (12-26) fused to penetratin CPP sequenceSarafraz-Yazdi 2022
Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994
Antibody development
—
—
02Dosage Protocols
Parameter
PNC-27
Sermorelin
Clinical status
Pre-clinical only — no human trials
In vitro and animal model data only.
—
In vitro concentrations
10–100 μM range
Effective concentrations in cell culture studies.
—
Shorter analogue
PNC-28 (28 AA variant)
Retains HDM-2 binding and cytotoxic activity.
—
Evidence basis
Pre-clinical / In vitro
Phase 3 (Geref pediatric); clinical practiceWalker 1994Molteno 2013
Frequency
—
Once daily, pre-sleep
Lower / starter dose
—
100 mcg per dose
Duration
—
8–12 weeks per cycle
Reconstitution
—
Bacteriostatic water
Timing
—
Pre-sleep, fasted preferred
03Metabolic / Fat Loss Evidence
Parameter
PNC-27
Sermorelin
Fat loss mechanism
None — cytotoxic anticancer agent
—
04Side Effects & Safety
Parameter
PNC-27
Sermorelin
Human safety data
None available — no human trials conducted
—
Normal cell selectivity
In vitro: no cytotoxicity to normal cells (MCF-10-2A, peripheral blood mononuclear cells)Sarafraz-Yazdi 2010Thadi 2020
Normal cells express minimal membrane HDM-2.
—
Cancer cell specificity
Depends on membrane HDM-2 expression levels
Ovarian cancer lines with low membrane HDM-2 showed <30% necrosis.
—
Mitochondrial effects
Secondary mitochondrial membrane disruption in cancer cells
—
Injection site reaction
—
Mild erythema, transient pain
Flushing / headache
—
Common transient effect
IGF-1 elevation
—
Modest at standard doses
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis)
Pregnancy / OB
—
Avoid
Glucose handling
—
Generally neutral
Absolute Contraindications
PNC-27
- ·Human use — no clinical trials or safety data
Sermorelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
PNC-27
—Sermorelin
- ·Untreated diabetes
05Administration Protocol
Parameter
PNC-27
Sermorelin
1. Pre-clinical status
PNC-27 has not been tested in human subjects. All data derive from in vitro cancer cell line studies and limited animal models. No approved clinical formulation, dosing protocol, or safety profile exists.Pincus 2024
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Cell culture protocols
In vitro studies used 10–100 μM PNC-27 dissolved in cell culture medium. Peptide was added directly to cancer cell cultures (pancreatic, breast, colon, ovarian, leukemia lines) and incubated for 24–72 hours.
SQ — abdomen or thigh. Rotate sites.
3. Fluorescent labeling studies
Dual-labeled PNC-27 (green on N-terminus, red on C-terminus) demonstrated intact peptide binding to cancer cell membranes with combined yellow fluorescence at 30 minutes, persisting during cell lysis.Sookraj 2010
Pre-sleep, fasted.
4. Membrane HDM-2 requirement
Cytotoxicity correlates directly with membrane HDM-2 expression levels. Blocking HDM-2's p53-binding domain (1-109) with monoclonal antibodies prevents PNC-27-induced necrosis.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
—
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
PNC-27
— no documented stacks
Sermorelin
+ Ipamorelin
StrongSermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.
- Sermorelin
- 200–300 mcg SQ · pre-sleep
- Ipamorelin
- 200–300 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation, recovery, body composition